Response assessment in acute myeloid leukemia by flow cytometry supersedes cytomorphology at time of aplasia, amends cases without molecular residual disease marker and serves as an independent prognostic marker at time of aplasia and post-induction

類似資料

• 5-AZACITIDINE IN HIGH RISK MYELODYSPLASTIC SYNDROME-SINGLE CENTER EXPERIENCE
  著者:: I. Mandac Smoljanovic, 等
  出版事項: (2024-01-01)
• Comparison of cytomorphology and histomorphology in myelodysplastic syndromes
  著者:: Kathrin Nachtkamp, 等
  出版事項: (2024-04-01)
• Myelodysplastic syndromes and autoimmune phenomena – case report and literature overview
  著者:: Ana Zelić Kerep, 等
  出版事項: (2023-03-01)
• EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up for Myelodysplastic Syndromes
  著者:: Arjan A. van de Loosdrecht, 等
  出版事項: (2022-03-01)
• DIAGNOSTIC UTILITY OF FLOW CYTOMETRY IN MYELODYSPLASTIC SYNDROMES.
  著者:: Matteo Della Porta, 等
  出版事項: (2017-02-01)